查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1339165

品牌仿製藥市場,份額,規模,趨勢,行業分析報告:按藥物類別,應用,給藥途徑,分銷管道,地區,細分市場,預測2023-2032 年

Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class ; By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032
出版日期: | 出版商: Polaris Market Research | 英文 117 Pages | 商品交期: 最快1-2個工作天內

價格

根據 Polaris Market Research 的一項新研究，到 2032 年，全球品牌仿製藥市場預計將達到 4,108.6 億美元。該報告提供了對當前市場動態的詳細見解，並對未來市場成長進行了分析。

糖尿病、高血壓和癌症等慢性病發病率的上升推動了對藥品的需求。品牌仿製藥正在成為慢性病患者的熱門選擇，因為它們提供了比昂貴的品牌藥更實惠的替代品。仿製藥的傳播也是推動品牌仿製藥市場的因素之一。

仿製藥已越來越被醫生和患者接受，因為它們在品質、安全性和有效性方面可與品牌藥相媲美。政府促進使用仿製藥以降低整體醫療成本的措施也促進了品牌仿製藥市場的成長。世界各國政府正在推廣使用仿製藥，以降低醫療保健成本，並使患者更容易負擔得起藥物。

傳染病和非傳染性疾病負擔的增加以及老年人口的增加預計將對醫療保健行業的成長產生積極影響。糖尿病、高血壓和肥胖等慢性病在世界各地變得越來越普遍，而人口老化更容易患上這些疾病。

因此，對醫療保健服務和產品（包括品牌仿製藥）的需求預計將大幅增加。例如，據美國癌症研究所估計，2021 年全球將有 3,700 萬癌症患者。糖尿病是一種慢性疾病，需要持續的治療和管理。品牌仿製藥正在成為糖尿病患者的熱門選擇，因為它們提供了比昂貴的品牌藥物更實惠的替代品。

高血壓也是一種慢性病，多發於中老年人。據世界衛生組織 (WHO) 稱，高血壓影響全球 10 億人，預計到 2025 年將增加到 15 億。品牌仿製藥為高血壓提供了負擔得起的治療選擇，並正在推動市場需求。

品牌仿製藥市場報告亮點

由於老年人心臟病發病率的增加以及更便宜的替代品的出現，抗高血壓藥物佔據了最大份額

由於口服藥物具有護理經驗少、患者接受度高等優點，口服藥物市場佔有很大的市場份額。

零售藥局銷售份額預計擴大，主要由於新興市場零售藥局數量增加

由於對低成本藥物的偏好日益增加，預計亞太地區在研究期間將出現高成長率

目錄

第 1 章 簡介

第二章執行摘要

第三章研究方法論

第四章全球品牌仿製藥市場洞察

  • 品牌仿製藥市場－通路快照
  • 品牌學名藥市場動態
    • 驅動因素和機遇
      • 慢性病患病率增加
      • 過期專利增加
    • 限制因素和挑戰
      • 嚴格的監管政策和品牌藥的巨大競爭
  • PESTEL 分析
  • 品牌仿製藥市場通路的趨勢
  • 價值鏈分析
  • COVID-19 感染的影響分析

第五章全球品牌仿製藥市場（依藥物類別）

  • 主要發現
  • 介紹
  • 烷基化劑
  • 抗代謝藥
  • 激素
  • 降壓藥
  • 降血脂藥
  • 抗憂鬱藥
  • 抗精神病藥
  • 抗癲癇藥
  • 其他

第六章 全球品牌仿製藥市場（按應用）

  • 主要發現
  • 介紹
  • 腫瘤學
  • 心血管疾病
  • 神經系統疾病
  • 消化系統疾病
  • 皮膚病
  • 急性和慢性疼痛
  • 其他

第七章 全球品牌仿製藥市場（依通路）

  • 主要發現
  • 介紹
  • 當地的
  • 口服
  • 腸外

第八章全球品牌仿製藥市場（按地區）

  • 主要發現
  • 介紹
    • 品牌仿製藥市場評估（按地區），2019-2032
  • 品牌仿製藥市場 - 北美
    • 北美：品牌仿製藥市場，按藥物類別劃分，2019-2032 年
    • 北美：品牌仿製藥市場，依通路劃分，2019-2032 年
    • 北美：品牌仿製藥市場，按應用劃分，2019-2032 年
    • 品牌仿製藥市場 - 美國
    • 品牌仿製藥市場 - 加拿大
  • 品牌仿製藥市場 - 歐洲
    • 歐洲：品牌仿製藥市場，依藥物類別，2019-2032
    • 歐洲：品牌仿製藥市場，依通路劃分，2019-2032 年
    • 歐洲：品牌仿製藥市場，依應用劃分，2019-2032
    • 品牌學名藥市場－英國
    • 品牌仿製藥市場－法國
    • 品牌仿製藥市場 - 德國
    • 品牌仿製藥市場—義大利
    • 品牌學名藥市場－西班牙
    • 品牌仿製藥市場－荷蘭
    • 品牌仿製藥市場 - 俄羅斯
  • 品牌仿製藥市場 – 亞太地區
    • 亞太地區：品牌仿製藥市場，依藥物類別劃分，2019-2032 年
    • 亞太地區：品牌仿製藥市場，依通路劃分，2019-2032 年
    • 亞太地區：品牌仿製藥市場，按應用劃分，2019-2032 年
    • 品牌仿製藥市場 - 中國
    • 品牌仿製藥市場—印度
    • 品牌學名藥市場－馬來西亞
    • 品牌仿製藥市場 - 日本
    • 品牌仿製藥市場 - 印度尼西亞
    • 品牌學名藥市場 - 韓國
  • 品牌仿製藥市場 - 中東和非洲
    • 中東和非洲：品牌仿製藥市場，按藥物類別，2019-2032 年
    • 中東和非洲：品牌仿製藥市場，按分銷管道劃分，2019-2032 年
    • 中東和非洲：品牌仿製藥市場，按應用劃分，2019-2032 年
    • 品牌學名藥市場－沙烏地阿拉伯
    • 品牌學名藥市場－阿拉伯聯合大公國
    • 品牌學名藥市場－以色列
    • 品牌仿製藥市場—南非
  • 品牌仿製藥市場 - 拉丁美洲
    • 拉丁美洲：品牌仿製藥市場，按藥物類別劃分，2019-2032 年
    • 拉丁美洲：品牌仿製藥市場，按分銷管道劃分，2019-2032 年
    • 拉丁美洲：品牌仿製藥市場，按應用劃分，2019-2032 年
    • 品牌仿製藥市場—墨西哥
    • 品牌仿製藥市場—巴西
    • 品牌仿製藥市場—阿根廷

第9章 競爭格局

  • 擴張和收購分析
    • 擴張
    • 獲得
  • 夥伴關係/協作/協議/揭露

第十章公司簡介

  • Teva Pharmaceutical
  • Lupin
  • Sanofi
  • Sun Pharmaceutical Industries
  • Dr. Reddy's Laboratories
  • Endo International
  • GlaxoSmithKline
  • Pfizer
  • Apotex
  • Viatris, Inc.
Product Code: PM3545

The global branded generics market size is expected to reach USD 410.86 billion by 2032, according to a new study by Polaris Market Research. The report "Branded Generics Market Share, Size, Trends, Industry Analysis Report, By Drug Class (Alkylating Agents, Antimetabolites, Anti-Hypertensive); By Application; By Route of Administration; By Distribution Channel; By Region, And Segment Forecasts, 2023 - 2032" gives a detailed insight into current market dynamics and provides analysis on future market growth.

Increasing rates of chronic diseases such as diabetes, hypertension, and cancer are driving the demand for drugs. Branded generics are becoming a popular choice for patients suffering from chronic illnesses as they offer a more affordable alternative to expensive brand-name drugs. The widespread use of generic drugs is another factor driving the branded generics market.

Generic drugs have become more widely accepted by both physicians and patients as they are equivalent in quality, safety, and efficacy to their brand-name counterparts. Government initiatives promoting the use of generic drugs to reduce overall healthcare costs are also driving the growth of the branded generics market. Governments worldwide are promoting the use of generic drugs to lower healthcare costs and increase access to affordable medicines for patients.

Growing burden of infectious and non-infectious diseases, along with the rising geriatric population, is expected to have a positive impact on the healthcare industry's growth. Chronic diseases such as diabetes, hypertension, and obesity are becoming more prevalent worldwide, and the geriatric population is more susceptible to these diseases.

As a result, the demand for healthcare services and products, including branded generics, is expected to increase significantly. According to an NCBI article, there were 537 million patients suffering from diabetes globally in 2021. Diabetes is a chronic disease that requires ongoing medical care and management. Branded generics are becoming a popular choice for diabetic patients as they offer a more affordable alternative to expensive brand-name drugs.

Hypertension is another chronic disease that is prevalent among the geriatric population. According to the World Health Organization (WHO), hypertension impacts 1 Bn people globally, and this is expected to rise to 1.5 Bn, by 2025. Branded generics offer an affordable treatment option for hypertension, which is driving their demand in the market.

Branded Generics Market Report Highlights

Anti-hypersensitive segment accounted for the largest share, owing to rise in cardiac ailments among geriatrics, and availability of low-cost alternatives

Oral segment accounted for the larger market share, owing to the advantages of oral based drug administration with minimal nursing experience, with high accept patient acceptability

Retail pharmacy is projected to experience larger revenue share, primarily due to increase in number of retail pharmacies in the developed markets

APAC is projected to register a higher growth rate in the study period, due to increase in preference of low-cost medicines

The global players include: Teva Pharmaceutical, Lupin, Sanofi, Sun Pharmaceutical Industries, Dr. Reddy's Laboratories, Endo International, GlaxoSmithKline, Pfizer, Apotex, and Viatris, Inc.

Polaris Market Research has segmented the branded generics market report based on drug class, application, route of administration, by distribution channel, and region:

Branded Generics, Drug Class Outlook (Revenue - USD Billion, 2019 - 2032)

  • Alkylating Agents
  • Antimetabolites
  • Hormones
  • Anti-Hypertensive
  • Lipid Lowering Drugs
  • Anti-Depressants
  • Anti-Psychotics
  • Anti-Epileptics
  • Others

Branded Generics, Application Outlook (Revenue - USD Billion, 2019 - 2032)

  • Oncology
  • Cardiovascular Diseases
  • Neurological Diseases
  • Gastrointestinal Diseases
  • Dermatological Diseases
  • Acute and Chronic Pain
  • Others

Branded Generics, Route of Administration Outlook (Revenue - USD Billion, 2019 - 2032)

  • Topical
  • Oral
  • Parenteral
  • Others

Branded Generics, Distribution Channel Industry Outlook (Revenue - USD Billion, 2019 - 2032)

  • Hospital Pharmacy
  • Retail Pharmacy
  • Online Pharmacy

Branded Generics, Regional Outlook (Revenue - USD Billion, 2019 - 2032)

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • Russia
  • Netherlands
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Indonesia
  • Malaysia
  • Latin America
  • Argentina
  • Brazil
  • Mexico
  • Middle East & Africa
  • UAE
  • Saudi Arabia
  • Israel
  • South Africa

Table of Contents

1. Introduction

  • 1.1. Report Description
    • 1.1.1. Objectives of the Study
    • 1.1.2. Market Scope
    • 1.1.3. Assumptions
  • 1.2. Stakeholders

2. Executive Summary

  • 2.1. Market Highlights

3. Research Methodology

  • 3.1. Overview
    • 3.1.1. Data Mining
  • 3.2. Data Distribution Channels
    • 3.2.1. Primary Distribution Channels
    • 3.2.2. Secondary Distribution Channels

4. Global Branded Generics Market Insights

  • 4.1. Branded Generics Market - Distribution Channel Snapshot
  • 4.2. Branded Generics Market Dynamics
    • 4.2.1. Drivers and Opportunities
      • 4.2.1.1. Increasing prevalence rate of chronic diseases
      • 4.2.1.2. Rising number of expired patents
    • 4.2.2. Restraints and Challenges
      • 4.2.2.1. Strict regulatory policies and huge competition from branded drugs
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of Suppliers (Moderate)
    • 4.3.2. Threats of New Entrants: (Low)
    • 4.3.3. Bargaining Power of Buyers (Moderate)
    • 4.3.4. Threat of Substitute (Moderate)
    • 4.3.5. Rivalry among existing firms (High)
  • 4.4. PESTEL Analysis
  • 4.5. Branded Generics Market Distribution Channel Trends
  • 4.6. Value Chain Analysis
  • 4.7. COVID-19 Impact Analysis

5. Global Branded Generics Market, by Drug Class

  • 5.1. Key Findings
  • 5.2. Introduction
    • 5.2.1. Global Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • 5.3. Alkylating Agents
    • 5.3.1. Global Branded Generics Market, by Alkylating Agents, by Region, 2019-2032 (USD Billion)
  • 5.4. Antimetabolites
    • 5.4.1. Global Branded Generics Market, by Antimetabolites, by Region, 2019-2032 (USD Billion)
  • 5.5. Hormones
    • 5.5.1. Global Branded Generics Market, by Hormones, by Region, 2019-2032 (USD Billion)
  • 5.6. Anti-Hypertensive
    • 5.6.1. Global Branded Generics Market, by Anti-Hypertensive, by Region, 2019-2032 (USD Billion)
  • 5.7. Lipid Lowering Drugs
    • 5.7.1. Global Branded Generics Market, by Lipid Lowering Drugs, by Region, 2019-2032 (USD Billion)
  • 5.8. Anti-Depressants
    • 5.8.1. Global Branded Generics Market, by Anti-Depressants, by Region, 2019-2032 (USD Billion)
  • 5.9. Anti-Psychotics
    • 5.9.1. Global Branded Generics Market, by Anti-Psychotics, by Region, 2019-2032 (USD Billion)
  • 5.10. Anti-Epileptics
    • 5.10.1. Global Branded Generics Market, by Anti-Epileptics, by Region, 2019-2032 (USD Billion)
  • 5.11. Others
    • 5.11.1. Global Branded Generics Market, by Others, by Region, 2019-2032 (USD Billion)

6. Global Branded Generics Market, by Application

  • 6.1. Key Findings
  • 6.2. Introduction
    • 6.2.1. Global Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 6.3. Oncology
    • 6.3.1. Global Branded Generics Market, by Oncology, by Region, 2019-2032 (USD Billion)
  • 6.4. Cardiovascular Diseases
    • 6.4.1. Global Branded Generics Market, by Cardiovascular Diseases, by Region, 2019-2032 (USD Billion)
  • 6.5. Neurological Diseases
    • 6.5.1. Global Branded Generics Market, by Neurological Diseases, by Region, 2019-2032 (USD Billion)
  • 6.6. Gastrointestinal Diseases
    • 6.6.1. Global Branded Generics Market, by Gastrointestinal Diseases, by Region, 2019-2032 (USD Billion)
  • 6.8. Dermatological Diseases
    • 6.8.1. Global Branded Generics Market, by Dermatological Diseases, by Region, 2019-2032 (USD Billion)
  • 6.9. Acute and Chronic Pain
    • 6.9.1. Global Branded Generics Market, by Acute and Chronic Pain, by Region, 2019-2032 (USD Billion)
  • 6.10. Others
    • 6.10.1. Global Branded Generics Market, by Others, by Region, 2019-2032 (USD Billion)

7. Global Branded Generics Market, by Distribution Channel

  • 7.1. Key Findings
  • 7.2. Introduction
    • 7.2.1. Global Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • 7.3. Topical
    • 7.3.1. Global Branded Generics Market, by Topical, By Region, 2019-2032 (USD Billion)
  • 7.4. Oral
    • 7.4.1. Global Branded Generics Market, by Oral, By Region, 2019-2032 (USD Billion)
  • 7.5. Parenteral
    • 7.5.1. Global Branded Generics Market, by Parenteral, By Region, 2019-2032 (USD Billion)
  • 7.6. Oral
    • 7.6.1. Global Branded Generics Market, by Oral, By Region, 2019-2032 (USD Billion)

8. Global Branded Generics Market, by Geography

  • 8.1. Key findings
  • 8.2. Introduction
    • 8.2.1. Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • 8.3. Branded Generics Market - North America
    • 8.3.1. North America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.3.2. North America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.3.3. North America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.3.4. Branded Generics Market - U.S.
      • 8.3.4.1. U.S.: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.4.2. U.S.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.4.3. U.S.: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.3.5. Branded Generics Market - Canada
      • 8.3.5.1. Canada: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.3.5.2. Canada.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.3.5.3. Canada: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.4. Branded Generics Market - Europe
    • 8.4.1. Europe: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.4.2. Europe.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.4.3. Europe: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.4. Branded Generics Market - UK
      • 8.4.4.1. UK: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.4.2. UK.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.4.3. UK: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.5. Branded Generics Market - France
      • 8.4.5.1. France: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.5.2. France.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.5.3. France: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.6. Branded Generics Market - Germany
      • 8.4.6.1. Germany: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.6.2. Germany.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.6.3. Germany: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.7. Branded Generics Market - Italy
      • 8.4.7.1. Italy: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.7.2. Italy.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.7.3. Italy: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.8. Branded Generics Market - Spain
      • 8.4.8.1. Spain: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.8.2. Spain.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.8.3. Spain: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.9. Branded Generics Market - Netherlands
      • 8.4.9.1. Netherlands: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.9.2. Netherlands.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.9.3. Netherlands: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.4.10. Branded Generics Market - Russia
      • 8.4.10.1. Russia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.4.10.2. Russia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.4.10.3. Russia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.5. Branded Generics Market - Asia Pacific
    • 8.5.1. Asia Pacific: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.5.2. Asia Pacific.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.5.3. Asia Pacific: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.4. Branded Generics Market - China
      • 8.5.4.1. China: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.4.2. China.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.4.3. China: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.5. Branded Generics Market - India
      • 8.5.5.1. India: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.5.2. India.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.5.3. India: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.6. Branded Generics Market - Malaysia
      • 8.5.6.1. Malaysia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.6.2. Malaysia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.6.3. Malaysia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.7. Branded Generics Market - Japan
      • 8.5.7.1. Japan: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.7.2. Japan.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.7.3. Japan: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.8. Branded Generics Market - Indonesia
      • 8.5.8.1. Indonesia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.8.2. Indonesia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.8.3. Indonesia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.5.9. Branded Generics Market - South Korea
      • 8.5.9.1. South Korea: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.5.9.2. South Korea.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.5.9.3. South Korea: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.6. Branded Generics Market - Middle East & Africa
    • 8.6.1. Middle East & Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.6.2. Middle East & Africa.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.6.3. Middle East & Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.4. Branded Generics Market - Saudi Arabia
      • 8.6.4.1. Saudi Arabia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.4.2. Saudi Arabia.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.4.3. Saudi Arabia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.5. Branded Generics Market - UAE
      • 8.6.5.1. UAE: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.5.2. UAE.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.5.3. UAE: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.6. Branded Generics Market - Israel
      • 8.6.6.1. Israel: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.6.2. Israel.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.6.3. Israel: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.6.7. Branded Generics Market - South Africa
      • 8.6.7.1. South Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.6.7.2. South Africa.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.6.7.3. South Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • 8.7. Branded Generics Market - Latin America
    • 8.7.1. Latin America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
    • 8.7.2. Latin America.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
    • 8.7.3. Latin America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.4. Branded Generics Market - Mexico
      • 8.7.4.1. Mexico: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.4.2. Mexico.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.4.3. Mexico: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.5. Branded Generics Market - Brazil
      • 8.7.5.1. Brazil: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.5.2. Brazil.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.5.3. Brazil: Branded Generics Market, by Application, 2019-2032 (USD Billion)
    • 8.7.6. Branded Generics Market - Argentina
      • 8.7.6.1. Argentina: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
      • 8.7.6.2. Argentina.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
      • 8.7.6.3. Argentina: Branded Generics Market, by Application, 2019-2032 (USD Billion)

9. Competitive Landscape

  • 9.1. Expansion and Acquisition Analysis
    • 9.1.1. Expansion
    • 9.1.2. Acquisitions
  • 9.2. Partnerships/Collaborations/Agreements/Exhibitions

10. Company Profiles

  • 10.1. Teva Pharmaceutical
    • 10.1.1. Company Overview
    • 10.1.2. Financial Performance
    • 10.1.3. Drug Class Benchmarking
    • 10.1.4. Recent Development
  • 10.2. Lupin
    • 10.2.1. Company Overview
    • 10.2.2. Financial Performance
    • 10.2.3. Drug Class Benchmarking
    • 10.2.4. Recent Development
  • 10.3. Sanofi
    • 10.3.1. Company Overview
    • 10.3.2. Financial Performance
    • 10.3.3. Drug Class Benchmarking
    • 10.3.4. Recent Development
  • 10.4. Sun Pharmaceutical Industries
    • 10.4.1. Company Overview
    • 10.4.2. Financial Performance
    • 10.4.3. Drug Class Benchmarking
    • 10.4.4. Recent Development
  • 10.5. Dr. Reddy's Laboratories
    • 10.5.1. Company Overview
    • 10.5.2. Financial Performance
    • 10.5.3. Drug Class Benchmarking
    • 10.5.4. Recent Development
  • 10.6. Endo International
    • 10.6.1. Company Overview
    • 10.6.2. Financial Performance
    • 10.6.3. Drug Class Benchmarking
    • 10.6.4. Recent Development
  • 10.7. GlaxoSmithKline
    • 10.7.1. Company Overview
    • 10.7.2. Financial Performance
    • 10.7.3. Drug Class Benchmarking
    • 10.7.4. Recent Development
  • 10.8. Pfizer
    • 10.8.1. Company Overview
    • 10.8.2. Financial Performance
    • 10.8.3. Drug Class Benchmarking
    • 10.8.4. Recent Development
  • 10.9. Apotex
    • 10.9.1. Company Overview
    • 10.9.2. Financial Performance
    • 10.9.3. Drug Class Benchmarking
    • 10.9.4. Recent Development
  • 10.10. Viatris, Inc.
    • 10.10.1. Company Overview
    • 10.10.2. Financial Performance
    • 10.10.3. Drug Class Benchmarking
    • 10.10.4. Recent Development

List of Tables

  • Table 1 Global Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 2 Global Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 3 Global Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 4 Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Table 5 North America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 6 North America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 7 North America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 8 U.S.: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 9 U.S.: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 10 U.S.: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 11 Canada: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 12 Canada: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 13 Canada: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 14 Europe: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 15 Europe: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 16 Europe: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 17 UK: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 18 UK: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 19 UK: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 20 France: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 21 France: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 22 France: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 23 Germany: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 24 Germany: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 25 Germany: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 26 Italy: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 27 Italy: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 28 Italy: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 29 Spain: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 30 Spain: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 31 Spain: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 32 Netherlands: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 33 Netherlands: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 34 Netherlands: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 35 Russia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 36 Russia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 37 Russia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 38 Asia Pacific: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 39 Asia Pacific: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 40 Asia Pacific: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 41 China: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 42 China: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 43 China: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 44 India: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 45 India: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 46 India: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 47 Malaysia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 48 Malaysia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 49 Malaysia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 50 Japan: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 51 Japan: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 52 Japan: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 53 Indonesia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 54 Indonesia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 55 Indonesia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 56 South Korea: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 57 South Korea: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 58 South Korea: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 59 Middle East & Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 60 Middle East & Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 61 Middle East & Africa: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 62 Saudi Arabia: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 63 Saudi Arabia: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 64 Saudi Arabia: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 65 UAE: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 66 UAE: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 67 UAE: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 68 Israel: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 69 Israel: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 70 Israel: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 71 South Africa: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 72 South Africa: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 73 South Africa: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 74 Latin America: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 75 Latin America: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 76 Latin America: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 77 Mexico: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 78 Mexico: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 79 Mexico: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 80 Brazil: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 81 Brazil: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 82 Brazil: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)
  • Table 83 Argentina: Branded Generics Market, by Drug Class, 2019-2032 (USD Billion)
  • Table 84 Argentina: Branded Generics Market, by Application, 2019-2032 (USD Billion)
  • Table 85 Argentina: Branded Generics Market, by Distribution Channel, 2019-2032 (USD Billion)

List of Figures

  • Figure 1. Global Branded Generics Market, 2019-2032 (USD Billion)
  • Figure 2. Integrated Ecosystem
  • Figure 3. Research Methodology: Top-Down & Bottom-Up Approach
  • Figure 4. Market by Geography
  • Figure 5. Porter's Five Forces
  • Figure 6. Market by Application
  • Figure 7. Global Branded Generics Market, by Application, 2022 & 2032 (USD Billion)
  • Figure 8. Market by Drug Class
  • Figure 9. Global Branded Generics Market, by Drug Class, 2022 & 2032 (USD Billion)
  • Figure 10. Market by Distribution Channel
  • Figure 11. Global Branded Generics Market, by Distribution Channel, 2022 & 2032 (USD Billion)
  • Figure 12. Branded Generics Market Assessment, By Geography, 2019-2032 (USD Billion)
  • Figure 13. Strategic Analysis - Branded Generics Market